6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid | 873445-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid
• 英文别名: 6-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]hexanoic acid
• CAS: 873445-19-3
• 化学式: C₁₉H₂₃ClN₂O₂
• 分子量: 346.857
• InChiKey: DISVIQCPBLUMPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid 、 色胺盐酸盐 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以44%的产率得到6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexanoic acid [2-(1H-indol-3-yl)-ethyl]-amide
  参考文献：
  名称：

  Novel Tacrine−Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties

  摘要：

  Tacrine and melatonin are well-known drugs with activities as an acetylcholinesterase (AChE) inhibitor and free radical scavenger, respectively. In this work, we report new hybrids of both drugs that display higher in vitro properties than the sum of their parts. As selective inhibitors of human AChE, their IC50 values range from sub-nanomolar to picomolar. They exhibit a higher oxygen radical absorbance capacity than does melatonin and are predicted to be able to cross the blood-brain barrier to reach their targets in the central nervous system.

  DOI：

  10.1021/jm050746d
• 作为产物：
  描述：

  6-氨基己酸 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid
  参考文献：
  名称：

  Novel Tacrine−Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties

  摘要：

  Tacrine and melatonin are well-known drugs with activities as an acetylcholinesterase (AChE) inhibitor and free radical scavenger, respectively. In this work, we report new hybrids of both drugs that display higher in vitro properties than the sum of their parts. As selective inhibitors of human AChE, their IC50 values range from sub-nanomolar to picomolar. They exhibit a higher oxygen radical absorbance capacity than does melatonin and are predicted to be able to cross the blood-brain barrier to reach their targets in the central nervous system.

  DOI：

  10.1021/jm050746d

文献信息

• Tacrine-allyl/propargylcysteine–benzothiazole trihybrids as potential anti-Alzheimer's drug candidates
  作者：Asha Hiremathad、Karam Chand、A. Raquel Esteves、Sandra M. Cardoso、Rona R. Ramsay、Sílvia Chaves、Rangappa S. Keri、M. Amélia Santos

  DOI：10.1039/c6ra03455a

  日期：——

  On continuing our research on new drug candidates for Alzheimer´s disease (AD), we have designed, synthesized and evaluated a series of multifunctional trihybrid agents. The design strategy was based on...

  在继续研究针对阿尔茨海默氏病（AD）的新候选药物时，我们已经设计，合成和评估了一系列多功能三杂化剂。设计策略基于...
• Novel Tacrine−Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties
  作者：María Isabel Rodríguez-Franco、María Isabel Fernández-Bachiller、Concepción Pérez、Blanca Hernández-Ledesma、Begoña Bartolomé

  DOI：10.1021/jm050746d

  日期：2006.1.1

  Tacrine and melatonin are well-known drugs with activities as an acetylcholinesterase (AChE) inhibitor and free radical scavenger, respectively. In this work, we report new hybrids of both drugs that display higher in vitro properties than the sum of their parts. As selective inhibitors of human AChE, their IC50 values range from sub-nanomolar to picomolar. They exhibit a higher oxygen radical absorbance capacity than does melatonin and are predicted to be able to cross the blood-brain barrier to reach their targets in the central nervous system.